AU6142186A - Use of melatonin or related compounds for the treatment of psoriasis - Google Patents

Use of melatonin or related compounds for the treatment of psoriasis

Info

Publication number
AU6142186A
AU6142186A AU61421/86A AU6142186A AU6142186A AU 6142186 A AU6142186 A AU 6142186A AU 61421/86 A AU61421/86 A AU 61421/86A AU 6142186 A AU6142186 A AU 6142186A AU 6142186 A AU6142186 A AU 6142186A
Authority
AU
Australia
Prior art keywords
melatonin
psoriasis
treatment
related compounds
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU61421/86A
Inventor
Walter Pierpaoli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cellena (Cell Engineering) AG
Original Assignee
Cellena (Cell Engineering) AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellena (Cell Engineering) AG filed Critical Cellena (Cell Engineering) AG
Publication of AU6142186A publication Critical patent/AU6142186A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
AU61421/86A 1985-07-16 1986-07-16 Use of melatonin or related compounds for the treatment of psoriasis Abandoned AU6142186A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB858517958A GB8517958D0 (en) 1985-07-16 1985-07-16 Compositions containing melatonin/homologues
GB8517958 1985-07-16

Publications (1)

Publication Number Publication Date
AU6142186A true AU6142186A (en) 1987-02-10

Family

ID=10582374

Family Applications (1)

Application Number Title Priority Date Filing Date
AU61421/86A Abandoned AU6142186A (en) 1985-07-16 1986-07-16 Use of melatonin or related compounds for the treatment of psoriasis

Country Status (4)

Country Link
EP (1) EP0229131A1 (en)
AU (1) AU6142186A (en)
GB (1) GB8517958D0 (en)
WO (1) WO1987000432A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4861794A (en) * 1988-04-13 1989-08-29 Pfizer Inc. 3-substituted-2-oxindole-1-carboxamides as inhibitors of interleukin-1 biosynthesis
IL95880A (en) * 1989-10-13 1995-12-31 Pfizer Use of 3-substituted-2-oxindole derivatives for the preparation of a pharmaceutical preparation for inhibiting interleukin-1 biosynthesis
JPH03145419A (en) * 1989-10-31 1991-06-20 Shiseido Co Ltd Drug of preventing ultraviolet light aging
IT1243846B (en) * 1990-10-17 1994-06-28 Pulitzer Italiana THERAPEUTIC ACTIVITY OF MELATONIN DERIVED IN DERMATOLOGY.
US5146710A (en) * 1991-02-20 1992-09-15 Caldwell Wesley A Parking space control
US5508039A (en) * 1991-10-18 1996-04-16 Alza Corporation Controlled transdermal administration of melatonin
IT1254995B (en) * 1992-06-24 1995-10-11 DRUG CONTAINING MELATONIN AND / OR AGONISTS, WITH PARTICULARLY EFFECTIVE ADMINISTRATION IN PATHOLOGIES THAT INTERFER WITH CIRCANDIAN RHYTHMS
US5385736A (en) * 1993-07-12 1995-01-31 Minnesota Mining And Manufacturing Company Transdermal melatonin delivery system
EP0711553A1 (en) * 1994-08-09 1996-05-15 Mario Cagnoni Use of the Melatonin in the traetment of the articular symptoms of trheumatoid arthritis
WO1997006779A1 (en) * 1995-08-11 1997-02-27 Kistler Gonzague S Protection from ultraviolet (uv) radiation-induced skin damage by topical treatment with melatonin (n-acetyl-5-metroxytryptamine)
FR2741802B1 (en) * 1995-12-04 1998-01-02 Oreal USE OF MELATONIN TO TREAT SENSITIVE SKIN
FR2751539B1 (en) * 1996-07-25 1998-12-04 Oreal NOVEL TOPICAL COMPOSITIONS COMPRISING VERY LOW DOSE OF MELATONIN OR DERIVATIVES THEREOF AND THEIR USE IN COSMETICS
FR2751535B1 (en) * 1996-07-25 1998-11-27 Oreal USE OF MELATONIN DERIVATIVES FOR DEPIGMENTATION OF THE SKIN AND COMPOSITIONS COMPRISING THE SAME
FR2753095B1 (en) * 1996-09-06 1998-11-20 Oreal USE OF MELATONIN AS AN ANTI-INFLAMMATORY AGENT IN A COSMETIC OR PHARMACEUTICAL COMPOSITION

Also Published As

Publication number Publication date
EP0229131A1 (en) 1987-07-22
WO1987000432A2 (en) 1987-01-29
GB8517958D0 (en) 1985-08-21
WO1987000432A3 (en) 1987-05-21

Similar Documents

Publication Publication Date Title
AU6022486A (en) Apparatus for trichologic treatment of the scalp
GB2188844B (en) Pharmaceutical composition for the treatment of psoriasis
AU6734987A (en) Treatment of emulsions
EP0385517A3 (en) Medicaments for the treatment of emesis
AU1676588A (en) Treatment of materials
FI874671A0 (en) ANORDINATION FOR THE CONDUCT OF THE TREATMENT.
AU591701B2 (en) Treatment of liquids
AU6123386A (en) Novel composition for the treatment of decubitus ulcers
AU1193288A (en) Composition for treatment of acne
AU5730286A (en) Treatment of factor viii inhibitors
AU6142186A (en) Use of melatonin or related compounds for the treatment of psoriasis
ZA867530B (en) Composition for the treatment of acne
AU590592B2 (en) Device for the treatment of substances by UV radiation
AU591903B2 (en) Novel treatment
AU2720388A (en) New therapeutical use of h2-receptor-blocking compounds
AU5893986A (en) Novel treatment
GB2165453B (en) Pharmaceutical agent for the local treatment of psoriasis
AU583927B2 (en) Treatment of horses
EP0419998A3 (en) Use of alkylphosphonic acid derivatives for the treatment of psoriasis
AU5259486A (en) Arylalkoxyphenyl-allylic alcohols as agents for the treatment of hypersensitive ailments
AU1541088A (en) Composition for the treatment of the epiderm
NZ255753A (en) Use of substituted azaspiranes for psoriasis treatment
AU5240886A (en) Sulphonyldihydropyridines for treatment of asthma
GB8524251D0 (en) Treatment for ulcers &c
GR3000306T3 (en) Composition for the treatment of infections